Summary of Presentations from the Daiichi Sankyo Satellite Symposium, held at the Annual ESC Congress, Barcelona, Spain, on 1st September 2014
Co-Chairs: Freek Verheugt,1 Christoph Bode2
Speakers: Gregory Lip,3 Raffaele De Caterina,4 Robert Giugliano5
1. Heart Lung Centre, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands
2. Heart Center Freiburg University, Freiburg, Germany
3. University of Birmingham, Birmingham, UK
4. “G. d’Annunzio” University, Chieti, Italy
5. Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA
Disclosure: Prof Gregory Lip has acted as a consultant for Bayer, Astellas, Merck, Sanofi, BMS/Pfizer, Biotronik, Medtronic, Portola, Boehringer Ingelheim, Microlife Medtronic, and Daiichi Sankyo. He has also been on the speakers’ bureau for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Microlife, and Daiichi Sankyo. Prof Raffaele De Caterina has received fees, honoraria, and research funding from Sanofi-Aventis, Boehringer Ingelheim, Bayer, BMS/Pfizer, Daiichi Sankyo, and Novartis. Prof Robert Giugliano has received research grant support from Daiichi Sankyo and Merck, and honoraria for lectures/consulting from Daiichi Sankyo, Merck, Janssen, Pfizer, and Sanofi.
Acknowledgements: Writing assistance provided by Dr Saroshi Amirthalingam, apothecom scopemedical Ltd.
Support: The publication of this article was funded by Daiichi Sankyo Europe GmbH. The views and opinions expressed are those of the authors and not necessarily of Daiichi Sankyo.
Citation: EMJ Cardiol. 2014;2:38-45.
Prof Gregory Lip opened the symposium with a discussion on determining stroke and bleeding risk in atrial fibrillation (AF) patients and their management. Prof Raffaele De Caterina presented data from the PREFER in AF registry and trends in the management of AF across Europe. Dr Robert Giugliano concluded with a presentation of the latest data from the ENGAGE AF-TIMI 48 trial.